Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash from Financing Activities (2020 - 2023)

Historic Cash from Financing Activities for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$121000.0.

  • Candel Therapeutics' Cash from Financing Activities fell 43611.11% to -$121000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was -$121000.0, marking a year-over-year decrease of 10060.58%. This contributed to the annual value of $94.3 million for FY2024, which is 7801735.54% up from last year.
  • Candel Therapeutics' Cash from Financing Activities amounted to -$121000.0 in Q4 2023, which was down 43611.11% from $36000.0 recorded in Q4 2022.
  • Over the past 5 years, Candel Therapeutics' Cash from Financing Activities peaked at $71.4 million during Q3 2021, and registered a low of -$121000.0 during Q4 2023.
  • Moreover, its 4-year median value for Cash from Financing Activities was $74000.0 (2021), whereas its average is $11.5 million.
  • Per our database at Business Quant, Candel Therapeutics' Cash from Financing Activities surged by 1768214.29% in 2022 and then crashed by 43611.11% in 2023.
  • Quarter analysis of 4 years shows Candel Therapeutics' Cash from Financing Activities stood at $29000.0 in 2020, then soared by 245951.72% to $71.4 million in 2021, then plummeted by 99.95% to $36000.0 in 2022, then tumbled by 436.11% to -$121000.0 in 2023.
  • Its Cash from Financing Activities stands at -$121000.0 for Q4 2023, versus $36000.0 for Q4 2022 and $22000.0 for Q2 2022.